ArticleToxicology and applied pharmacology2022
Circadian disruption and cisplatin chronotherapy for mammary carcinoma.
Article in Toxicology and applied pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Chronotherapeutic administration of neoadjuvant chemotherapy reduces cancer-related fatigue-like behavior.Brain, behavior, & immunity - health · 2026Article
- Circadian Controlled Transcription in Brain and Peripheral Organs of Juvenile and Adult Mice.International journal of molecular sciences · 2026Article
- Night shift work and breast cancer: from etiopathology to precision risk analysis.NPJ breast cancer · 2025Review
- Tuned by time: the role of circadian rhythms in metabolic energy sensing and chronotherapy.Annals of medicine · 2025Review
- Time of Day-Dependent Responses to Cisplatin Treatment in a Male Mouse Model of Hepatoma.Journal of biological rhythms · 2025Article
- Role of the period family in mediating the interplay between circadian disruption and cancer (Review).Oncology letters · 2025Review
- Prognostic value of circadian rhythm-associated genes in breast cancer.World journal of surgical oncology · 2025Article
- Metformin upregulates circadian gene PER2 to inhibit growth and enhance the sensitivity of glioblastoma cell lines to radiotherapy via SIRT2/G6PD pathway.Frontiers in pharmacology · 2025Article
- Circadian rhythms and breast cancer: from molecular level to therapeutic advancements.Journal of cancer research and clinical oncology · 2024Review
- A circadian rhythm-related lncRNA signature correlates with prognosis and tumor immune microenvironment in head and neck squamous cell carcinoma.Discover oncology · 2024Article
- Chronotherapeutics for Solid Tumors.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Solid tumors are commonly treated with cisplatin, which can cause off-target side effects in cancer patients. Chronotherapy is a potential strategy to reduce drug toxicity. To determine the effectiveness of timed-cisplatin treatment in mammals, we compared two conditions: clock disrupted jet-lag and control conditions. Under normal and disrupted clock conditions, triple-negative mammary carcinoma cells were injected subcutaneously into eight-week-old NOD.Cg-Prkdc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.